Radiation necrosis with stereotactic radiosurgery combined with CTLA-4 blockade and PD-1 inhibition for treatment of intracranial disease in metastatic melanoma. (Q50651030)

From Wikidata

Jump to navigation Jump to search

scientific article published on 12 May 2017

Language	Label	Description	Also known as
English	Radiation necrosis with stereotactic radiosurgery combined with CTLA-4 blockade and PD-1 inhibition for treatment of intracranial disease in metastatic melanoma.	scientific article published on 12 May 2017

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28500560%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Radiation necrosis with stereotactic radiosurgery combined with CTLA-4 blockade and PD-1 inhibition for treatment of intracranial disease in metastatic melanoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28500560%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

metastatic melanoma

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28500560%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28500560%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

author name string

Penny Fang

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28500560%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Pamela Allen

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28500560%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Isabella Glitza

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28500560%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Nandita Guha

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28500560%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Patrick Hwu

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28500560%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Amol Ghia

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28500560%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Anita Mahajan

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28500560%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Hussein Tawbi

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28500560%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Jing Li

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28500560%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

publication date

12 May 2017

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28500560%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Journal of Neuro-Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28500560%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

133

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28500560%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28500560%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

595-602

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28500560%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

https://scigraph.springernature.com/pub.10.1007/s11060-017-2470-4

0 references

Determinants of survival in patients with brain metastases from cutaneous melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS11060-017-2470-4

21 January 2018

Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens

1 reference

https://api.crossref.org/works/10.1007%2FS11060-017-2470-4

21 January 2018

Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS11060-017-2470-4

21 January 2018

Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial

1 reference

https://api.crossref.org/works/10.1007%2FS11060-017-2470-4

21 January 2018

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

1 reference

https://api.crossref.org/works/10.1007%2FS11060-017-2470-4

21 January 2018

Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial

1 reference

https://api.crossref.org/works/10.1007%2FS11060-017-2470-4

21 January 2018

Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases

1 reference

https://api.crossref.org/works/10.1007%2FS11060-017-2470-4

21 January 2018

Long-term risk of radionecrosis and imaging changes after stereotactic radiosurgery for brain metastases

1 reference

https://api.crossref.org/works/10.1007%2FS11060-017-2470-4

21 January 2018

Does immunotherapy increase the rate of radiation necrosis after radiosurgical treatment of brain metastases?

1 reference

https://api.crossref.org/works/10.1007%2FS11060-017-2470-4

21 January 2018

Ipilimumab and Stereotactic Radiosurgery Versus Stereotactic Radiosurgery Alone for Newly Diagnosed Melanoma Brain Metastases.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-017-2470-4

21 January 2018

Ipilmumab and cranial radiation in metastatic melanoma patients: a case series and review.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-017-2470-4

21 January 2018

Symptomatic Histologically Proven Necrosis of Brain following Stereotactic Radiation and Ipilimumab in Six Lesions in Four Melanoma Patients

1 reference

https://api.crossref.org/works/10.1007%2FS11060-017-2470-4

21 January 2018

Gamma knife stereotactic radiosurgery in the treatment of brainstem metastases: The MD Anderson experience

1 reference

https://api.crossref.org/works/10.1007%2FS11060-017-2470-4

21 January 2018

Survival of melanoma patients with brain metastases treated with ipilimumab and stereotactic radiosurgery

1 reference

https://api.crossref.org/works/10.1007%2FS11060-017-2470-4

21 January 2018

Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-017-2470-4

21 January 2018

Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery

1 reference

https://api.crossref.org/works/10.1007%2FS11060-017-2470-4

21 January 2018

Adverse radiation effect after stereotactic radiosurgery for brain metastases: incidence, time course, and risk factors

1 reference

https://api.crossref.org/works/10.1007%2FS11060-017-2470-4

21 January 2018

BRAF inhibitor and stereotactic radiosurgery is associated with an increased risk of radiation necrosis

1 reference

https://api.crossref.org/works/10.1007%2FS11060-017-2470-4

21 January 2018

Initial experience with combined BRAF and MEK inhibition with stereotactic radiosurgery for BRAF mutant melanoma brain metastases.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-017-2470-4

21 January 2018

Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05

1 reference

https://pubmed.ncbi.nlm.nih.gov/28500560

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S11060-017-2470-4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28500560%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28500560%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50651030&oldid=1460554269"